Safety, cost and effectiveness issues with disease modifying anti- rheumatic drugs in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Fries, James F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT;

COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG COST; DRUG RESEARCH; DRUG SAFETY; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0032732056     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.2008.i86     Document Type: Review

References (12)

1. Fries JF. The ARAMIS (American Rheumatism Association Medical Information System) Post-Marketing Surveillance Program. Drug Information Journal 1985;19:257-62.
2. Fries JF. The chronic disease data bank model: A conceptual framework for the computerbased medical record. Comp Biomed Res 1992;25:586-601.
3. Williams CA, Bloch DA, Sibley J, et al. Lymphoma and leukemia in rheumatoid arthritis: Are they associated with azathioprine, cyclophosphamide, or methotrexate? A matched case-comrol study in the Arthritis, Rheumatism and Aging Medical Information System (ARAMIS) population. J Clin Rheumatol 1996;2:64-72.
4. Fries JF, Williams CA, Bloch DA. The relative toxicity of non-steroidal anti-inflammatory drugs (NSAIDs). Arthritis Rheum 1991;34:1353-60.
5. Fries JF, Spitz PW, Williams CA, Bloch DA, Singh G, Hubert HB. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990;33:121-30.
6. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease modifying antirheumatic drugs (DMARDs). Arthritis Rheum 1993;36:297-306.
7. Fries JF. Toward an understanding of patient outcome measurement. Arthritis Rheum 1983;26:697-704.
8. Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995 - Status and Review. 2nd ed. Spilker B, ed. Pharmacoeconomics and quality of life in clinical trials. New York: Raven Press, 1996;227-37.
9. Fries JIF. Non-steroidal anti-inflammatory drug safety: a view from the ARAMIS databank. Curr Opin Rheumatol 1996;9:S3-8.
10. Fries JF. Effectiveness and toxicity considerations in outcome-directed therapy in rheumatoid arthritis. J Rheumatol 1996;23:102-6.
11. Fries JF, Williams CA, Ramey DR, Singh G. Medical costs are strongly associated with disability levels in rheumatoid arthritis (RA). Arthritis Rheum 1995;38:S187.
12. Albert DA, Aksentijevich S, Hurst S, Fries JF, Wolfe F. Modeling therapeutic strategies in rheumatoid arthritis: Use of decision analysis and Markov models. Arthritis Rheum 1998;41:S227.